VKTX
What one share of Viking Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
Viking Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$4.67 |
| Cash and investments | $1.08 |
| Book value | $3.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$0.91 | — | −$0.68 | — | $0.39 |
| 2017 | $0.00 | −$0.79 | — | −$0.57 | — | $0.38 |
| 2018 | $0.00 | −$0.38 | — | −$0.33 | — | $4.15 |
| 2019 | $0.00 | −$0.36 | — | −$0.34 | — | $3.83 |
| 2020 | $0.00 | −$0.54 | — | −$0.30 | — | $3.34 |
| 2021 | $0.00 | −$0.71 | — | −$0.62 | — | $2.58 |
| 2022 | $0.00 | −$0.90 | — | −$0.63 | — | $1.86 |
| 2023 | $0.00 | −$0.91 | — | −$0.78 | — | $3.48 |
| 2024 | $0.00 | −$1.01 | — | −$0.81 | — | $7.89 |
| 2025 | $0.00 | −$3.19 | — | −$2.47 | — | $5.57 |